AUR-AF94-TTP1-A-1-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- MYOGENESIS+0.410
- UV_RESPONSE_DN+0.320
- TGF_BETA_SIGNALING+0.230
- HEDGEHOG_SIGNALING+0.220
- ESTROGEN_RESPONSE_EARLY+0.190
- NOTCH_SIGNALING+0.180
- APICAL_JUNCTION+0.160
- IL6_JAK_STAT3_SIGNALING+0.150
Top 10 suppressed
- MYC_TARGETS_V2-0.570
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.460
- OXIDATIVE_PHOSPHORYLATION-0.450
- ADIPOGENESIS-0.400
- FATTY_ACID_METABOLISM-0.400
- E2F_TARGETS-0.380
- CHOLESTEROL_HOMEOSTASIS-0.370
- MYC_TARGETS_V1-0.370
- BILE_ACID_METABOLISM-0.340
- GLYCOLYSIS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 102d912c-5882-4ae4-9eaf-cbd2f55f66af | — | — | 0.863 |
| 2 | 6b32f047-89ca-40e7-950f-a03493ea90c7 | — | — | 0.859 |
| 3 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.855 |
| 4 | 4108a871-c064-4537-9331-e59798d7d492 | — | — | 0.855 |
| 5 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.855 |
| 6 | 023160e4-1d9a-499c-9bfa-1b3aacf284f2 | — | — | 0.848 |
| 7 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.846 |
| 8 | a307b24f-4caa-403a-8313-2a4604f2079a | — | — | 0.844 |
| 9 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.843 |
| 10 | f65f4ed5-9726-4eff-8638-63752686d2c9 | — | — | 0.842 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.160 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.120 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.060 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.050 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.030 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |